Just In: ( NASDAQ: #MDGL ) 2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026

Breaking News: ( NASDAQ: #MDGL ) 2 Predictions for Novo Nordisk in 2026

#MDGL Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/MDGL/madrigal-pharm...

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis Madrigal Pharmaceuticals (NASDAQ:MDGL) has received European Commission approval for Rezdiffra (resmetirom), making it the first and only approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis in the European Union.The conditional marketing authorization is based on successful Phase 3 MAESTRO-NASH trial results, where 91% of patients treated with Rezdiffra 100 mg showed improvement or stabilization of liver stiffness at one year. The once-daily oral treatment targets approximately 370,000 diagnosed patients across Europe.Madrigal plans to launch Rezdiffra in Europe starting with Germany in Q4 2025, with other EU countries, Iceland, Liechtenstein, and Norway to follow based on individual reimbursement procedures.

#MDGL Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

www.stocktitan.net/news/MDGL/madrigal-recei...

Madrigal (MDGL) Q2 Revenue Soars 1,313% | The Motley Fool

#MDGL #7e7203be-dfe2-477f-938c-fe9b99ad2584 #data-news

Origin | Interest | Match

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates Madrigal Pharmaceuticals (NASDAQ:MDGL) reported strong Q2 2025 financial results, with Rezdiffra net sales reaching $212.8 million. The company achieved several significant milestones, including receiving a new U.S. patent extending Rezdiffra's protection until 2045, securing a $500 million senior secured credit facility, and obtaining a positive CHMP opinion for European approval.Key financial metrics include cash position of $802.0 million as of June 30, 2025. Operating expenses were $260.0 million, with SG&A expenses at $196.9 million and R&D expenses at $54.1 million. The company expanded its pipeline through a global licensing agreement for an oral GLP-1 development candidate and presented promising two-year F4c MASH clinical data at EASL Congress.

#MDGL Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/MDGL/madrigal-pharm...

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited Madrigal Pharmaceuticals (NASDAQ:MDGL) has secured an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral GLP-1 receptor agonist. The deal involves an upfront payment of $120 million and potential milestone payments up to $2 billion, plus royalties.The agreement aligns with Madrigal's strategy to develop combination treatments for MASH (Metabolic dysfunction-Associated SteatoHepatitis), building upon their foundational therapy Rezdiffra™. Clinical development is planned to begin in first half of 2026. The combination aims to leverage GLP-1's weight loss benefits with Rezdiffra's fibrosis and lipid reduction capabilities in a once-daily oral formulation.

#MDGL Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

www.stocktitan.net/news/MDGL/madrigal-pharm...

First FDA-Approved MASH Drug Rezdiffra Gets 20-Year Patent Protection: What This Means for Madrigal New patent strengthens Madrigal's market position for breakthrough MASH treatment Rezdiffra. Covers FDA-approved dosing regimen with Orange Book listing. See impact.

#MDGL Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

www.stocktitan.net/news/MDGL/madrigal-pharm...

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis Madrigal Pharmaceuticals (MDGL) received a positive opinion from EMA's CHMP recommending approval of resmetirom (Rezdiffra) for treating adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The European Commission's final decision is expected in August 2025. If approved, resmetirom will become the first approved MASH treatment in the EU. The drug, which received FDA accelerated approval in March 2024, demonstrated positive results in the Phase 3 MAESTRO-NASH trial, achieving both fibrosis reduction and MASH resolution endpoints. Resmetirom is a once-daily, oral, liver-directed THR-β agonist designed to target underlying causes of MASH, which is the fastest-growing indication for liver transplantation in Europe.

#MDGL Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

www.stocktitan.net/news/MDGL/madrigal-recei...

PT2 of pattern concepts

#ABDL #NSFW #DDLG #MDGL #Diaperlover #diapergirl #AdultBaby #CGL #Kink #cottagecore

I hinted this ages ago, but I'm slowly working on a personal project of making a onesie design. Would there be an interest in having more cottage core like designs? Simple, nostalgic and calming?

#ABDL #NSFW #DDLG #MDGL #Diaperlover #diapergirl #AdultBaby #CGL #Kink #cottagecore

www.fool.com/investing/2025/05/13/2-m...

#VKTX #MDGL […]

[Original post on fool.com]

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10) Appointed David Soergel, M.D., to

#MDGL Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

www.stocktitan.net/news/MDGL/madrigal-pharm...

#If u think today's move in #MDGL means u missed it, here are the EPS estimates just for Rezdiffra going out to 2029 when - maybe - other MASH drugs may finally be ready for the current indication. And the est have not yet been updated based on today's report.

You guys didn't believe me, did you?
#MDGL

a man in a suit and tie says that he is dead serious ALT: a man in a suit and tie says that he is dead serious

YUGE EPS day tomorrow... #MDGL ... before the open.
What...?

More front-running of an "M&A Monday" in #MDGL . I'm pretty sure it's gonna happen, probably this year, but not sure bidding it up on Th/Fri and sell it back on the following Mon until there's a deal, is the way to go. Factoid: 4 H/Funds now own 40% of the stk.

#MDGL trying for a new all-time closing high. $7.5B mkt cap, w/ an approved drug in line for $500M+ in sales this yr (launched 6mths ago) and $1B+ in '26. Not too many biotechs this cheap and de-risked imho.

Earnings Alert: Madrigal Pharmaceuticals Sets Key Q4 Financial Results Date - Mark Your Calendar Madrigal Pharmaceuticals schedules Q4 and full-year 2024 earnings release, with management hosting live discussion webcast on February 26 at 8 AM ET.

#MDGL Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

www.stocktitan.net/news/MDGL/madrigal-pharm...

#MDGL has already closed the gap from yday's home-run data by #AKRO . There's plenty of room for multiple drugs for #MASH , and as good as EFX' Ph2b results look, it's gonna be a couple of years b4 it gets to market, and by the MDGL will almost certainly exist under a different ticker.

Old Style Random Thoughts Update Been a long week so far today

Forgot to link article this a.m. so you get the new and improved version 😅 filzucchi.substack.com/p/old-style-... #SPY #QQQ #CEG #GEV #QCOM #MU #AKRO #MDGL #NVDA #PRIM #VRT

2/ If not stat sig, but showing improvement consistent w/36w results, I'll stick my neck out that #AKRO Stk reaction won't be anything like Oct'23. Either way, imo this data will be very telling for the whole program, and how EFX may ultimately compete w/ #MDGL #ETNB

1/ The Oct '23 36w readout of EFX Ph2b crushed #AKRO stk despite what looked like pretty impressive data given the short time to readout & the tough pts pop it's tackling. The 96w readout is coming in Feb. If stat sign - despite study not being powered for that - stk cud/shud fly... #ETNB #MDGL

BREAKING NEWS: ( NASDAQ: #MDGL ) Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Madrigal's Rezdiffra Achieves $180M Sales in First Year as Groundbreaking MASH Treatment Madrigal reports strong Q4 sales of $103M for Rezdiffra, the first-approved MASH therapy. With $931M cash and 11,800+ patients, European expansion planned for late 2025.

#MDGL Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

www.stocktitan.net/news/MDGL/madrigal-pharm...

NEWS: ( NASDAQ: #MDGL ) 3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

#StockMarket #News

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#NTLA, #SE, #INDI, #APP, #MDGL

#OptionFlow #OptionsTrading #Trading